Arthritis Foundation Central PA Chapter

90
Arthritis Foundation Central PA Chapter
Arthritis Foundation Central PA Chapter is listed in the Foundations Educational Philanthropic Research Etc category in Harrisburg, Pennsylvania. Displayed below are the social networks for Arthritis Foundation Central PA Chapter which include a Facebook page, a Instagram account, a Linkedin company page and a Twitter account. The activity and popularity of Arthritis Foundation Central PA Chapter on these social networks gives it a ZapScore of 90.

Contact information for Arthritis Foundation Central PA Chapter is:
3544 N Progress Ave
Harrisburg, PA 17110
(717) 763-0903

"Arthritis Foundation Central PA Chapter" - ZapScore Report

90
Arthritis Foundation Central PA Chapter has an overall ZapScore of 90. This means that Arthritis Foundation Central PA Chapter has a higher ZapScore than 90% of all businesses on Zappenin. For reference, the median ZapScore for a business in Harrisburg, Pennsylvania is 35 and in the Foundations Educational Philanthropic Research Etc category is 46. Learn more about ZapScore

Do you own or manage this business? Click here to claim the Arthritis Foundation Central PA Chapter listing and add social networks, logos, descriptions and more.

Arthritis Foundation Central PA Chapter Contact Information:

Social Posts for Arthritis Foundation Central PA Chapter

Today, the president released the administration’s official budget request for fiscal year 2018. The proposed budget would have severe implications for Medicaid and other programs that deliver vital health care services to people with arthritis. We're committed to breaking down barriers to care for all people with arthritis. That's why we're calling on Congress to protect the lives of all Americans by rejecting the president’s budget and declaring a strong commitment to public health in fiscal year 2018. Read more in our official statement below:
This budget would cut nearly $6 billion from the National Institutes of Health (NIH), with more than $120 million of those cuts impacting the National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS). These cuts would severely hinder


Read Our Statement on the Official FY 2018 President’s Budget Request bit.ly/2qSYEwj


RT @NIH_NIAMS: Guy Eakin @ArthritisFdn & Martin Kriegel @Yale present Delivering on Discovery Program: Lupus Update at #LFWG https://t.co/O…


Patient-Centered #Arthritis Research: Join us & @PCORI for a great discussion + we'll answer your questions LIVE! twitter.com/i/web/status/8…


RT @PCORI: What does comparative effectiveness research have to offer patients with #arthritis and their caregivers? Find out on @periscope…

According to a recent study, losing excess weight may help preserve knee cartilage in people who have or are at risk of knee osteoarthritis (OA). Learn more about how weight loss can protect your knee joint and slow the symptoms of knee OA:
Although many studies have looked at the effects of excess weight on the knee, Dr. Gersing says this is the first to examine the long-term effect of weight loss on cartilage and the menisci.


A new study found that losing excess weight may help preserve knee cartilage in ppl who have/are at risk of knee OA. bit.ly/2qSjRV4

Gout is a debilitating disease that impacts more than 8 million people every year, but there is hope! On National Gout Awareness Day, learn how you can Wipe Out Gout!
Don’t settle for enduring a lifetime of swelling and pain caused by gout. Learn tips and tools on how to talk to your doctor about gout - and see how zero gout flares may be possible.

Arthritis Foundation shared Walk To Cure Arthritis's post.
We want to give a big THANK YOU to everyone who came out and joined us at a Walk To Cure Arthritis event this weekend! We hope you had as much fun as we did!
What a wonderful day full of Walk to Cure Arthritis events across the country. Thank you to each and everyone of you who helped make these events such a huge success!

The U.S. Food and Drug Administration (FDA) has approved Renflexis, a biosimilar to Remicade, making it the 4th biosimilar approved to treat inflammatory types of arthritis. Learn more about Renflexis and when it will be available below:
Renflexis is the second approved biosimilar to Remicade. The first one, Inflectra (infliximab-dyyb), was approved in April 2016. This is the first time the FDA has approved two biosimilars for one original, “reference” medication.